The assessment of severity of liver fibrosis in HIV/HCV coinfected patients should be performed in all patients to determine urge for further treatment [15]; however, 46% of HIV/HCV coinfected patients did not undergo TE, and thus, had no access to modern IFN-free regimens, since until recently reimbursement of IFN-free treatment was primarily restricted to patients with SIGFIB in Austria. The gene discussed is IFNA1; the disease is Hepatic fibrosis.